

Clinical Design & Innovation; Office of the Chief Clinical Officer Dr Steevens' Hospital, D08 W2A8 E: <u>clinicaldesign@hse.ie</u>

4<sup>th</sup> April, 2025

Deputy Pádraig O'Sullivan, TD Dáil Éireann Leinster House Kildare Street Dublin 2

RE: PQ 16451/25

To ask the Minister for Health if she will support the establishment of a centre of excellence for the treatment of amyloidosis; and if she will make a statement on the matter.

## RE: PQ16453/25

To ask the Minister for Health when her Department will fund the amyloidosis model of care; and if she will make a statement on the matter

Dear Deputy O'Sullivan,

The Health Service Executive has been requested to reply directly to you in relation to the above representation, which you submitted to the HSE for response. I have consulted with the National Clinical Director for Integrated Care and the National Clinical Advisor and Group Lead (NCAGL), Acutes, on your question and have been informed that the following outlines the position.

The HSE Amyloidosis Model of Care was approved in 2022. Since then, there has been progress with the approval of pharmacological treatments included in this model of care, where relevant, through the HSE's medicines management approvals process.

When a model of care is approved it is then progressed to implementation operationally. There were a number of areas identified in the model of care that required funding in order to progress to implementation. Funding was sought to support phased implementation of this model through the HSE's national service planning process with the Department of Health in 2023. Unfortunately, this new service development submission did not secure funding at that time.

This submission would have been part of a number of submissions for funding for new service developments and final allocations for such developments would have been outlined in the Letter of Determination from the Minster of Health to the HSE.

However funding has been allocated to rare diseases in National Service Developments (NSDs) for 2025 and it is planned to consider how some of this funding could support Amyloidosis.

I trust this information is of assistance to you, but should you have any further queries please do not hesitate to contact me.

Yours sincerely

Anne Horgan General Manager